Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Oncosec Medical (ONCS)

Oncosec Medical (ONCS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 97,425
  • Shares Outstanding, K 23,032
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,280 K
  • 60-Month Beta 2.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 07/31/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.84 +129.89%
on 07/06/20
4.89 -13.50%
on 07/29/20
+2.26 (+114.72%)
since 07/02/20
3-Month
1.51 +180.13%
on 05/12/20
4.89 -13.50%
on 07/29/20
+2.55 (+151.79%)
since 05/05/20
52-Week
1.04 +307.12%
on 03/17/20
4.89 -13.50%
on 07/29/20
+2.16 (+104.35%)
since 08/05/19

Most Recent Stories

More News
OncoSec Appoints Kellie Malloy Foerter as Chief Operating Officer

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral DNA–based cancer immunotherapies, today announced that , previously...

ONCS : 4.23 (-2.76%)
OncoSec's Novel COVID-19 Vaccine Candidate Featured in 'Straight Talk' Program by NBC TV in Portland, Oregon

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral DNA–based cancer immunotherapies, today announced the promising...

ONCS : 4.23 (-2.76%)
OncoSec to be Featured in "Grand Rounds: a Webinar in Biotech and Specialty Pharma," Webinar Hosted by Alliance Global Partners

and , /PRNewswire/ -- (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the Company will be featured in a live webinar, "Grand Rounds: A Webinar in...

ONCS : 4.23 (-2.76%)
OncoSec Set to Join Russel Microcap® Index

and , /PRNewswire/ -- (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the Company is set to join the Russell Microcap Index at the conclusion of the...

ONCS : 4.23 (-2.76%)
OncoSec Presents Two Late-Breaking Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II

and , /PRNewswire/ --(Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today presented new data further demonstrating the power of OncoSec's next-generation interleukin-12...

ONCS : 4.23 (-2.76%)
OncoSec Expands KEYNOTE-890 Trial into First-Line Metastatic Triple Negative Breast Cancer (mTNBC) with TAVO™ and KEYTRUDA® Plus Chemotherapy

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that, based upon tumor...

MRK : 81.64 (-0.04%)
ONCS : 4.23 (-2.76%)
OncoSec to Present at Virtual Summer Investor Summit

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced that , President and...

ONCS : 4.23 (-2.76%)
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

The Virtual Summer Summit will take place on June 9-12, connecting 47 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below...

ACCO : 6.68 (+0.30%)
ALIM : 6.98 (+27.84%)
ANVS : 5.73 (-1.21%)
AQB : 3.17 (-8.65%)
ARTL : 1.2000 (+2.56%)
AVLNF : 0.0580 (+1.75%)
BLCM : 7.54 (+5.16%)
NDRA : 0.9947 (+3.09%)
EFOI : 5.95 (+5.50%)
EQ : 10.63 (+2.51%)
EXROF : 0.6969 (+2.49%)
HL : 6.42 (+6.12%)
HSII : 21.04 (+5.99%)
HSDT : 0.6144 (+4.03%)
HGBL : 2.7000 (+12.50%)
IPWR : 7.89 (-0.38%)
LINC : 5.38 (+1.89%)
MBII : 1.1600 (unch)
MLSS : 1.8700 (+1.63%)
MYSZ : 1.3500 (+0.75%)
NBEV : 2.32 (+3.11%)
ONCS : 4.23 (-2.76%)
OGEN : 1.1300 (-2.59%)
SFE : 6.09 (+3.92%)
SLS : 3.58 (+0.28%)
PIXY : 5.00 (+3.52%)
SGLB : 2.83 (+1.07%)
SOTK : 2.9700 (-2.62%)
TNXP : 1.2500 (+3.31%)
TGA : 0.6018 (+0.30%)
URG : 0.5652 (-4.19%)
OncoSec Strengthens IP Portfolio with Three New Patents Covering TAVO™ and Its Electroporation Gene Delivery System

and , /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late-stage intratumoral cancer immunotherapies, today announced Notices of Allowance...

ONCS : 4.23 (-2.76%)
OncoSec to Present Two Late-Breaking Pre-Clinical Abstracts on TAVO-PLUS at the American Association for Cancer Research (AACR) Virtual Annual Meeting II

and , /PRNewswire/ -- (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced that it will present new pre-clinical data demonstrating the utility of OncoSec's...

ONCS : 4.23 (-2.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ONCS with:

Business Summary

OncoSec Medical Incorporated is a biomedical company engaged in the designing, development and commercialization of therapeutic oncology products. It also develops novel OMS ElectroOncology therapies and OncoSec Medical System for the treatment of solid tumors. OncoSec Medical Incorporated is based in...

See More

Key Turning Points

2nd Resistance Point 4.51
1st Resistance Point 4.37
Last Price 4.23
1st Support Level 4.15
2nd Support Level 4.06

See More

52-Week High 4.89
Last Price 4.23
Fibonacci 61.8% 3.42
Fibonacci 50% 2.96
Fibonacci 38.2% 2.51
52-Week Low 1.04

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar